期刊文献+

340例代谢综合征患者的中医证素与微量白蛋白尿的相关性研究 被引量:5

Study on the correlation between the TCM syndrome element and microalbunminuria in metabolic syndrome
原文传递
导出
摘要 目的:探讨代谢综合征的中医证素与微量白蛋白尿的关系。方法:采集340例代谢综合征患者的四诊资料,应用"证素辨证"的方法,对四诊资料进行分析统计,同时检测微量白蛋白尿(MAU)。结果:①代谢综合征基本证素:气虚、血虚、阴虚、阳虚、津亏、痰、血瘀、湿、热、气滞、心、肝、脾、肺、肾。②影响MAU的因素有中医证素肾、阳虚、血瘀,标准回归系数分别为0.47(P<0.01)、0.42(P<0.01)、0.334(P<0.05)。结论:由此推测MAU可作为代谢综合征肾、阳虚的参考指标之一。 Objective: To investigate the relationships of the TCM syndrome element and microalbuminuria in metabolic syndrome(MS).Methods: Collected four diagnostic data of 340 cases of metabolic syndrome,adopt 'syndrome differentiation based on syndrome element' method to analysis the diagnostic informations by using statistic process,and detected microalbuminuria at the same time.Results: ①The common elements of metabolic syndrome: qi deficiency,blood deficiency,yin deficiency,yang deficiency,depletion of fluid,phlegm,blood stasis,dampness,heat,qi stagnation,heart,liver,spleen,lung and kidney.②Stepwise analysis showed that microalbum level was associated positively with kidney,yang deficiency and blood stasis.Standard regression coefficient were 0.47(P0.01),0.42(P0.01),0.334(P0.05).Conclusion: It can speculate that microalbunminuria can be used as an objective indexe of MS with kidney and yang deficiency.
出处 《中华中医药杂志》 CAS CSCD 北大核心 2011年第12期2943-2945,共3页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 国家中医药管理局科技项目(No.0607JP22) 福建省教育厅资助项目(No.JB06130 No.JA07112)~~
关键词 代谢综合征 证素 微量白蛋白尿 Metablic syndrome Syndrome element Microalbuminuria
  • 相关文献

参考文献5

二级参考文献25

  • 1张红叶,杨军,周北凡,武阳丰,李莹,陶寿淇.我国十组人群脑卒中危险因素的前瞻性研究[J].中国慢性病预防与控制,1996,4(4):150-152. 被引量:91
  • 2曹家琪 连志浩 等.队列(群组)研究.流行病学,第2版,第1卷[M].北京:人民卫生出版社,1995.190-206.
  • 3Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18.
  • 4Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468.
  • 5Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s.
  • 6Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517.
  • 7Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559.
  • 8Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591.
  • 9Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186.
  • 10Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236.

共引文献3945

同被引文献74

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部